A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines

Project: Research

Project Details

StatusActive
Effective start/end date25/01/24 → 23/01/26

Keywords

  • clinical trial
  • Urticaria
  • remibrutinib